A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 21, 2020

Primary Completion Date

August 10, 2022

Study Completion Date

January 15, 2023

Conditions

Advanced Pancreatic Cancer

Interventions

DRUG

Fluzoparib

PARP

DRUG

Fluzoparib placebo

Placebo

DRUG

mFOLFIRINOX

Trial Locations (2)

Fudan University Shanghai Cancer Center, Shanghai

Zhejiang Provincial People's Hospital, Hangzhou

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04228601 - A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter